Evolus (EOLS) Other financing activities (2018)

Evolus' (EOLS) quarterly Other financing activities came in at -$11.4 million in Q4 2018, down 200.0% on a QoQ basis from $11.4 million in Q3 2018.

Evolus (EOLS) Other financing activities (2018) Analysis & Trends

Evolus (EOLS) has 1 years of Other financing activities data on file, last reported at -$11.4 million in Q4 2018.

Quarterly Other financing activities changed N/A year-over-year to -$11.4 million in Q4 2018, while the trailing twelve-month figure through Dec 2019 was $30000.0 (down 99.95% YoY) and the FY2024 annual result came in at $4.9 million, up 2013.42% from the prior year.
Other financing activities declined to -$11.4 million in Q4 2018, from $11.4 million in the prior quarter.
In the past five years, Other financing activities ranged from a high of $56.3 million in Q1 2018 to a low of -$11.4 million in Q4 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.94 Bn	42.97 Bn	-
2	Teva Pharmaceutical Industries	43.08 Bn	39.43 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.87 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.60 Bn	22.80 Bn	5.10 Bn
5	United Therapeutics	22.12 Bn	19.46 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.50 Bn	15.11 Bn	935.80 Mn
8	Elanco Animal Health	11.69 Bn	11.16 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.13 Bn	9.96 Bn	-
10	Evolus	550.84 Mn	505.67 Mn	57.18 Mn

Download Data